NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

Under the deal, the Japanese pharmaceutical firm will use Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology to identify important biomarkers that can be used in the drug-discovery process.

Financial and other terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.